SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (1454)3/30/2009 9:12:38 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 2274
 
Chuckle.

The potential for this sucker is combined use, and FDA goal SHOULD BE to get a few safe drugs which patients can use for rotation.

I haven't been able to get through to the conference call. Two computers, both with config problems this a.m.

:-(

Please post impressions of the conference call, all! Thanks.



To: fred hayes who wrote (1454)3/30/2009 11:46:28 AM
From: A.J. Mullen  Read Replies (1) | Respond to of 2274
 
The wording of the release was a little misleading in one respect. Average weight loss achieved with the drug was indeed greater than 5%, but it wasn't 5% more than those on the placebo.

I thought the FDA requirements were alternatives. The way the stock is reacting, it looks as if each requirement had to be met.

Ashley


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News